1786 Stock Overview
SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan.
SciVision Biotech Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$46.45|
|52 Week High||NT$53.80|
|52 Week Low||NT$38.80|
|1 Month Change||-9.81%|
|3 Month Change||15.12%|
|1 Year Change||-7.19%|
|3 Year Change||-26.50%|
|5 Year Change||29.54%|
|Change since IPO||53.90%|
Recent News & Updates
|1786||TW Medical Equipment||TW Market|
Return vs Industry: 1786 exceeded the TW Medical Equipment industry which returned -10.7% over the past year.
Return vs Market: 1786 exceeded the TW Market which returned -19.3% over the past year.
|1786 Average Weekly Movement||6.0%|
|Medical Equipment Industry Average Movement||5.5%|
|Market Average Movement||5.2%|
|10% most volatile stocks in TW Market||8.4%|
|10% least volatile stocks in TW Market||2.5%|
Stable Share Price: 1786 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 1786's weekly volatility (6%) has been stable over the past year.
About the Company
|2001||n/a||Tai Xian Han||https://www.scivision.com.tw|
SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan. It offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. The company was founded in 2001 and is based in Kaohsiung, Taiwan.
SciVision Biotech Fundamentals Summary
|1786 fundamental statistics|
Is 1786 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1786 income statement (TTM)|
|Cost of Revenue||NT$177.64m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.69|
|Net Profit Margin||22.41%|
How did 1786 perform over the long term?See historical performance and comparison
3.1%Current Dividend Yield
Is 1786 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1786?
Other financial metrics that can be useful for relative valuation.
|What is 1786's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 1786's PE Ratio compare to its peers?
|1786 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
6612 ICARES Medicus
4155 OK Biotech
4129 United Orthopedic
6747 Brighten Optix
1786 SciVision Biotech
Price-To-Earnings vs Peers: 1786 is expensive based on its Price-To-Earnings Ratio (27.4x) compared to the peer average (22.8x).
Price to Earnings Ratio vs Industry
How does 1786's PE Ratio compare vs other companies in the TW Medical Equipment Industry?
Price-To-Earnings vs Industry: 1786 is expensive based on its Price-To-Earnings Ratio (27.4x) compared to the TW Medical Equipment industry average (18.6x)
Price to Earnings Ratio vs Fair Ratio
What is 1786's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||27.4x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1786's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 1786 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1786 (NT$46.45) is trading above our estimate of fair value (NT$31.78)
Significantly Below Fair Value: 1786 is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is SciVision Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SciVision Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine SciVision Biotech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
How has SciVision Biotech performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1786 has a large one-off gain of NT$30.5M impacting its June 30 2022 financial results.
Growing Profit Margin: 1786's current net profit margins (22.4%) are lower than last year (25.6%).
Past Earnings Growth Analysis
Earnings Trend: 1786 has become profitable over the past 5 years, growing earnings by 23.7% per year.
Accelerating Growth: 1786's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1786 had negative earnings growth (-10.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (19%).
Return on Equity
High ROE: 1786's Return on Equity (7.9%) is considered low.
Discover strong past performing companies
How is SciVision Biotech's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 1786's short term assets (NT$711.5M) exceed its short term liabilities (NT$212.3M).
Long Term Liabilities: 1786's short term assets (NT$711.5M) exceed its long term liabilities (NT$380.9M).
Debt to Equity History and Analysis
Debt Level: 1786 has more cash than its total debt.
Reducing Debt: 1786's debt to equity ratio has reduced from 53.5% to 21.1% over the past 5 years.
Debt Coverage: 1786's debt is well covered by operating cash flow (32.5%).
Interest Coverage: 1786's interest payments on its debt are well covered by EBIT (29.3x coverage).
Discover healthy companies
What is SciVision Biotech current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|SciVision Biotech Dividend Yield vs Market|
|Company (SciVision Biotech)||3.1%|
|Market Bottom 25% (TW)||2.6%|
|Market Top 25% (TW)||7.0%|
|Industry Average (Medical Equipment)||4.0%|
|Analyst forecast in 3 Years (SciVision Biotech)||n/a|
Notable Dividend: 1786's dividend (3.05%) is higher than the bottom 25% of dividend payers in the TW market (2.57%).
High Dividend: 1786's dividend (3.05%) is low compared to the top 25% of dividend payers in the TW market (7.03%).
Stability and Growth of Payments
Stable Dividend: 1786 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 1786's dividend payments have increased, but the company has only paid a dividend for 7 years.
Earnings Payout to Shareholders
Earnings Coverage: At its current payout ratio (83.7%), 1786's payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (112.1%), 1786's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Tai Xian Han
Tai Xian Han serves as a General Manager of Scivision Biotech Inc and serves as its Director.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
SciVision Biotech Inc.'s employee growth, exchange listings and data sources
- Name: SciVision Biotech Inc.
- Ticker: 1786
- Exchange: TWSE
- Founded: 2001
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: NT$2.965b
- Shares outstanding: 66.19m
- Website: https://www.scivision.com.tw
- SciVision Biotech Inc.
- 1, South 1st Road
- Cianjhen District
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|1786||TWSE (Taiwan Stock Exchange)||Yes||Common Stock||TW||TWD||Dec 2010|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/30 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.